肌层浸润性膀胱癌保留膀胱的综合治疗研究进展  

Advances in multimodality treatment of muscular-invasive bladder cancer for bladder preservation

作　　者：宋家璈 曾蜀雄(审校)[2] 张振声[2] 许传亮[2] SONG Jiaao;ZENG Shuxiong;ZHANG Zhensheng;XU Chuanliang(Naval Medical University,Shanghai,200433,China;Department of Urology,Changhai Hospital)

机构地区：[1]海军军医大学,上海200433 [2]上海长海医院泌尿外科

出　　处：《临床泌尿外科杂志》2020年第7期579-585,共7页Journal of Clinical Urology

基　　金：国家自然科学基金(No:81802515);上海市青年科技英才扬帆计划(No:18YF1422700);第二军医大学青年启动基金(No:2017QN11)。

摘　　要：膀胱癌是一种常见的泌尿系统肿瘤,其中肌层浸润性膀胱癌(muscle-invasivebladder cancer,MIBC)的治疗难度较大。根治性膀胱切除术(radical cystectomy,RC)加盆腔淋巴结清扫术(pelvic lymph node dissection,PLND)是治疗肌层浸润性膀胱癌的标准术式。但该手术存在手术难度大、并发症发生率高、术后生活质量差等问题。近年来,随着医疗技术水平的发展,逐渐出现了各种保留膀胱的综合治疗(bladder preservation therapies,BPT)及新辅助治疗手段。分子生物学的进展,包括免疫检查点抑制剂和生物标志物,将使膀胱癌的个性化治疗成为可能。联合多学科的综合保膀胱治疗方案有与RC相似的治疗效果,本文就肌层浸润性膀胱癌综合保留膀胱治疗相关进展进行综述。Bladder cancer is a common tumor in the urinary system. Muscle-invasive bladder cancer(MIBC) requires radical cystectomy(RC) with pelvic lymph node dissection, which is the standard treatment for MIBC. However, this is a complex operation with high complication rate and poor postoperative quality of life. With the development of medical technology, various bladder preservation therapies(BPT) and neoadjuvant therapies have emerged in recent years. Progressions in molecular biology, including immune checkpoint inhibitors and biomarkers, will make personalized treatment of bladder cancer possible. Recent studies revealed that multidisciplinary comprehensive multimodality BPT has resulted in similar oncological outcome to RC in selected patients. This article reviews the progress of multimodality BPT for MIBC.

关 键 词：浸润性 膀胱癌 保留膀胱 三联治疗 部分切除 

分 类 号：R737.14[医药卫生—肿瘤]